TY - JOUR A1 - Riederer, Peter A1 - Laux, Gerd T1 - MAO-inhibitors in Parkinson's Disease JF - Experimental Neurobiology N2 - Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's disease (PD). They have been used with or without levodopa (L-DOPA). Non-selective MAO-I due to their side-effect/adverse reaction profile, like tranylcypromine have limited use in the treatment of depression in PD, while selective, reversible MAO-A inhibitors are recommended due to their easier clinical handling. For the treatment of akinesia and motor fluctuations selective irreversible MAO-B inhibitors selegiline and rasagiline are recommended. They are safe and well tolerated at the recommended daily doses. Their main differences are related to (1) metabolism, (2) interaction with CYP-enzymes and (3) quantitative properties at the molecular biological/genetic level. Rasagiline is more potent in clinical practise and has a hypothesis driven more favourable side effect/adverse reaction profile due to its metabolism to aminoindan. Both selegiline and rasagiline have a neuroprotective and neurorestaurative potential. A head-to head clinical trial would be of utmost interest from both the clinical outcome and a hypothesis-driven point of view. Selegiline is available as tablet and melting tablet for PD and as transdermal selegiline for depression, while rasagiline is marketed as tablet for PD. In general, the clinical use of MAO-I nowadays is underestimated. There should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential. In line with this are recent innovative developments of MAO-I plus inhibition of acetylcholine esterase for Alzheimer's disease as well as combined MAO-I and iron chelation for PD. KW - selegiline KW - rasagiline KW - moclobemide KW - phenelzine KW - tranylcypromine KW - acetylcholine KW - Alzheimer disease KW - antidepressive agents KW - depression KW - freezing KW - head KW - indans KW - iron KW - levodopa KW - monoamine oxidase KW - monoamine oxidase inhibitors KW - Parkinson disease Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-140930 VL - 20 IS - 1 ER - TY - JOUR A1 - Bonn, Maria A1 - Schmitt, Angelika A1 - Asan, Esther T1 - Double and triple in situ hybridization for coexpression studies: combined fluorescent and chromogenic detection of neuropeptide Y (NPY) and serotonin receptor subtype mRNAs expressed at different abundance levels JF - Histochemistry and Cell Biology N2 - Multiple fluorescence in situ hybridization is the method of choice for studies aimed at determining simultaneous production of signal transduction molecules and neuromodulators in neurons. In our analyses of the monoamine receptor mRNA expression of peptidergic neurons in the rat telencephalon, double tyramide-signal-amplified fluorescence in situ hybridization delivered satisfactory results for coexpression analysis of neuropeptide Y (NPY) and serotonin receptor 2C (5-HT2C) mRNA, a receptor subtype expressed at high-to-moderate abundance in the regions analyzed. However, expression of 5-HT1A mRNA, which is expressed at comparatively low abundance in many telencephalic areas, could not be unequivocally identified in NPY mRNA-reactive neurons due to high background and poor signal-to-noise ratio in fluorescent receptor mRNA detections. Parallel chromogenic in situ hybridization provided clear labeling for 5-HT1A mRNA and additionally offered the possibility to monitor the chromogen deposition at regular time intervals to determine the optimal signal-to-noise ratio. We first developed a double labeling protocol combining fluorescence and chromogenic in situ hybridization and subsequently expanded this variation to combine double fluorescence and chromogenic in situ hybridization for triple labelings. With this method, we documented expression of 5-HT2C and/or 5-HT1A in subpopulations of telencephalic NPY-producing neurons. The method developed in the present study appears suitable for conventional light and fluorescence microscopy, combines advantages of fluorescence and chromogenic in situ hybridization protocols and thus provides a reliable non-radioactive alternative to previously published multiple labeling methods for coexpression analyses in which one mRNA species requires highly sensitive detection. KW - Triple in situ hybridization KW - Coexpression KW - NPY KW - 5-HT1A KW - 5-HT2C Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-135229 VL - 137 IS - 1 ER - TY - JOUR A1 - Van den Hove, Daniel A1 - Jakob, Sissi Brigitte A1 - Schraut, Karla-Gerlinde A1 - Kenis, Gunter A1 - Schmitt, Angelika Gertrud A1 - Kneitz, Susanne A1 - Scholz, Claus-Jürgen A1 - Wiescholleck, Valentina A1 - Ortega, Gabriela A1 - Prickaerts, Jos A1 - Steinbusch, Harry A1 - Lesch, Klaus-Peter T1 - Differential Effects of Prenatal Stress in 5-Htt Deficient Mice: Towards Molecular Mechanisms of Gene x Environment Interactions JF - PLoS ONE N2 - Prenatal stress (PS) has been shown to influence the development of the fetal brain and to increase the risk for the development of psychiatric disorders in later life. Furthermore, the variation of human serotonin transporter (5-HTT, SLC6A4) gene was suggested to exert a modulating effect on the association between early life stress and the risk for depression. In the present study, we used a 5-HttxPS paradigm to investigate whether the effects of PS are dependent on the 5-Htt genotype. For this purpose, the effects of PS on cognition, anxiety-and depression-related behavior were examined using a maternal restraint stress paradigm of PS in C57BL6 wild-type (WT) and heterozygous 5-Htt deficient (5-Htt +/-) mice. Additionally, in female offspring, a genome-wide hippocampal gene expression profiling was performed using the Affymetrix GeneChip (R) Mouse Genome 430 2.0 Array. 5-Htt +/- offspring showed enhanced memory performance and signs of reduced anxiety as compared to WT offspring. In contrast, exposure of 5-Htt +/- mice to PS was associated with increased depressive-like behavior, an effect that tended to be more pronounced in female offspring. Further, 5-Htt genotype, PS and their interaction differentially affected the expression of numerous genes and related pathways within the female hippocampus. Specifically, MAPK and neurotrophin signaling were regulated by both the 5-Htt +/- genotype and PS exposure, whereas cytokine and Wnt signaling were affected in a 5-Htt genotypexPS manner, indicating a genexenvironment interaction at the molecular level. In conclusion, our data suggest that although the 5-Htt +/- genotype shows clear adaptive capacity, 5-Htt +/- mice -particularly females-at the same time appear to be more vulnerable to developmental stress exposure when compared to WT offspring. Moreover, hippocampal gene expression profiles suggest that distinct molecular mechanisms mediate the behavioral effects of the 5-Htt genotype, PS exposure, and their interaction. KW - Serotonin transporter polymorphism KW - Acute tryptophan depletion KW - Anxiety-like behavior KW - Long-term depression KW - Knock-out mice KW - Major depression KW - Interferon-alpha KW - Physiological functions KW - Restraint stress KW - Bipolar disorder Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-135111 VL - 6 IS - 8 ER - TY - JOUR A1 - Gerlach, Manfred A1 - Maetzler, Walter A1 - Broich, Karl A1 - Hampel, Harald A1 - Rems, Lucas A1 - Reum, Torsten A1 - Riederer, Peter A1 - Stöffler, Albrecht A1 - Streffer, Johannes A1 - Berg, Daniela T1 - Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics JF - Journal of Neural Transmission N2 - Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of the development of disease-modifying treatments for Parkinson’s disease (PD). The German Society of Experimental and Clinical Neurotherapeutics (GESENT) has convened a Working Group to review the current status of proposed biomarkers of neurodegeneration according to the following criteria and to develop a consensus statement on biomarker candidates for evaluation of disease-modifying therapeutics in PD. The criteria proposed are that the biomarker should be linked to fundamental features of PD neuropathology and mechanisms underlying neurodegeneration in PD, should be correlated to disease progression assessed by clinical rating scales, should monitor the actual disease status, should be pre-clinically validated, and confirmed by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. To date, available data have not yet revealed one reliable biomarker to detect early neurodegeneration in PD and to detect and monitor effects of drug candidates on the disease process, but some promising biomarker candidates, such as antibodies against neuromelanin, pathological forms of α-synuclein, DJ-1, and patterns of gene expression, metabolomic and protein profiling exist. Almost all of the biomarker candidates were not investigated in relation to effects of treatment, validated in experimental models of PD and confirmed in independent studies. KW - Parkinson’s disease KW - Disease-modifying therapies KW - Neuroprotection KW - Biomarkers KW - Surrogate endpoints KW - Drug development KW - Disease progression Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133856 VL - 119 IS - 1 ER - TY - JOUR A1 - Rantamäki, Tomi A1 - Vesa, Liisa A1 - Antila, Hanna A1 - Di Lieto, Antonio A1 - Tammela, Päivi A1 - Schmitt, Angelika A1 - Lesch, Klaus-Peter A1 - Rios, Maribel A1 - Castrén, Eero T1 - Antidepressant Drugs Transactivate TrkB Neurotrophin Receptors in the Adult Rodent Brain Independently of BDNF and Monoamine Transporter Blockade JF - PLoS ONE N2 - Background: Antidepressant drugs (ADs) have been shown to activate BDNF (brain-derived neurotrophic factor) receptor TrkB in the rodent brain but the mechanism underlying this phenomenon remains unclear. ADs act as monoamine reuptake inhibitors and after prolonged treatments regulate brain bdnf mRNA levels indicating that monoamine-BDNF signaling regulate AD-induced TrkB activation in vivo. However, recent findings demonstrate that Trk receptors can be transactivated independently of their neurotrophin ligands. Methodology: In this study we examined the role of BDNF, TrkB kinase activity and monoamine reuptake in the AD-induced TrkB activation in vivo and in vitro by employing several transgenic mouse models, cultured neurons and TrkB-expressing cell lines. Principal Findings: Using a chemical-genetic TrkB(F616A) mutant and TrkB overexpressing mice, we demonstrate that ADs specifically activate both the maturely and immaturely glycosylated forms of TrkB receptors in the brain in a TrkB kinase dependent manner. However, the tricyclic AD imipramine readily induced the phosphorylation of TrkB receptors in conditional bdnf(-/-) knock-out mice (132.4+/-8.5% of control; P = 0.01), indicating that BDNF is not required for the TrkB activation. Moreover, using serotonin transporter (SERT) deficient mice and chemical lesions of monoaminergic neurons we show that neither a functional SERT nor monoamines are required for the TrkB phosphorylation response induced by the serotonin selective reuptake inhibitors fluoxetine or citalopram, or norepinephrine selective reuptake inhibitor reboxetine. However, neither ADs nor monoamine transmitters activated TrkB in cultured neurons or cell lines expressing TrkB receptors, arguing that ADs do not directly bind to TrkB. Conclusions: The present findings suggest that ADs transactivate brain TrkB receptors independently of BDNF and monoamine reuptake blockade and emphasize the need of an intact tissue context for the ability of ADs to induce TrkB activity in brain. KW - Serotonin transporter KW - Neuronal plasticity KW - Mood disorders KW - Messenger-RNA KW - Mouse-brain KW - Rat-brain KW - Activation KW - Depression KW - Mice KW - Insensitivity Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133746 VL - 6 IS - 6 ER - TY - JOUR A1 - Song, Ning-Ning A1 - Xiu, Jian-Bo A1 - Huang, Ying A1 - Chen, Jia-Yin A1 - Zhang, Lei A1 - Gutknecht, Lise A1 - Lesch, Klaus Peter A1 - Li, He A1 - Ding, Yu-Qiang T1 - Adult Raphe-Specific Deletion of Lmx1b Leads to Central Serotonin Deficiency JF - PLoS ONE N2 - The transcription factor Lmx1b is essential for the differentiation and survival of central serotonergic (5-HTergic) neurons during embryonic development. However, the role of Lmx1b in adult 5-HTergic neurons is unknown. We used an inducible Cre-LoxP system to selectively inactivate Lmx1b expression in the raphe nuclei of adult mice. Pet1-CreER(T2) mice were generated and crossed with Lmx1b(flox/flox) mice to obtain Pet1-CreER(T2); Lmx1b(flox/flox) mice (which termed as Lmx1b iCKO). After administration of tamoxifen, the level of 5-HT in the brain of Lmx1b iCKO mice was reduced to 60% of that in control mice, and the expression of tryptophan hydroxylase 2 (Tph2), serotonin transporter (Sert) and vesicular monoamine transporter 2 (Vmat2) was greatly down-regulated. On the other hand, the expression of dopamine and norepinephrine as well as aromatic L-amino acid decarboxylase (Aadc) and Pet1 was unchanged. Our results reveal that Lmx1b is required for the biosynthesis of 5-HT in adult mouse brain, and it may be involved in maintaining normal functions of central 5-HTergic neurons by regulating the expression of Tph2, Sert and Vmat2. KW - Molecular-genetics KW - Sonic hedgehog KW - Neurons KW - Mice KW - Brain KW - Expression KW - System KW - PET-1 KW - Transporter KW - Disorders Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133581 VL - 6 IS - 1 ER - TY - JOUR A1 - Haeussinger, Florian B. A1 - Heinzel, Sebastian A1 - Hahn, Tim A1 - Schecklmann, Martin A1 - Ehlis, Ann-Christine A1 - Fallgatter, Andreas J. T1 - Simulation of Near-Infrared Light Absorption Considering Individual Head and Prefrontal Cortex Anatomy: Implications for Optical Neuroimaging JF - PLoS ONE N2 - Functional near-infrared spectroscopy (fNIRS) is an established optical neuroimaging method for measuring functional hemodynamic responses to infer neural activation. However, the impact of individual anatomy on the sensitivity of fNIRS measuring hemodynamics within cortical gray matter is still unknown. By means of Monte Carlo simulations and structural MRI of 23 healthy subjects (mean age: (25.0 +/- 2.8) years), we characterized the individual distribution of tissue-specific NIR-light absorption underneath 24 prefrontal fNIRS channels. We, thereby, investigated the impact of scalp-cortex distance (SCD), frontal sinus volume as well as sulcal morphology on gray matter volumes (V(gray)) traversed by NIR-light, i.e. anatomy-dependent fNIRS sensitivity. The NIR-light absorption between optodes was distributed describing a rotational ellipsoid with a mean penetration depth of (23.6 +/- 0.7) mm considering the deepest 5% of light. Of the detected photon packages scalp and bone absorbed (96.4 +/- 9: 7)% and V(gray) absorbed (3.1 +/- 1.8)% of the energy. The mean V(gray) volume (1.1 +/- 0.4)cm(3) was negatively correlated (r = - .76) with the SCD and frontal sinus volume (r = - .57) and was reduced by 41.5% in subjects with relatively large compared to small frontal sinus. Head circumference was significantly positively correlated with the mean SCD (r = .46) and the traversed frontal sinus volume (r = .43). Sulcal morphology had no significant impact on V(gray). Our findings suggest to consider individual SCD and frontal sinus volume as anatomical factors impacting fNIRS sensitivity. Head circumference may represent a practical measure to partly control for these sources of error variance. KW - Beer-lambert law KW - Adult head KW - Human brain KW - Spectroscopy fnirs KW - Photon migration KW - Propagation KW - Scattering KW - Model KW - Tissues KW - Media Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142311 VL - 6 IS - 10 ER - TY - JOUR A1 - Goepel, Johanna A1 - Biehl, Stefanie C. A1 - Kissler, Johanna A1 - Paul-Jordanov, Isabelle T1 - Pro- and antisaccades in children elicited by visual and acoustic targets - does modality matter? JF - BMC Pediatrics N2 - Background: Children are able to inhibit a prepotent reaction to suddenly arising visual stimuli, although this skill is not yet as pronounced as it is in adulthood. However, up to now the inhibition mechanism to acoustic stimuli has been scarcely investigated Methods: Reflexive (prosaccade) and inhibitory (antisaccade) responses to visual and acoustic targets were examined with an eye tracker system in 31 children between seven and twelve years of age using a gap-overlap task and two target eccentricities. Results: Acoustically cued saccades had longer reaction times than visually cued saccades. A gap effect (i.e., shorter reaction time in the gap than the overlap condition) was only found for visually elicited saccades, whereas an eccentricity effect (i.e., faster saccades to more laterally presented targets - 12 degrees vs. 6 degrees or rather 90 degrees vs. 45 degrees) was only present in the acoustic condition. Longer reaction times of antisaccades compared to prosaccades were found only in the visual task. Across both tasks the typical pattern of elevated error rates in the antisaccade condition was found. Antisaccade errors declined with age, indicating an ongoing development of inhibitory functions. Conclusions: The present results lay the ground for further studies of acoustically triggered saccades in typically as well as atypically developing children and it might thus be possible to upgrade physiological diagnostic tools. KW - Saccadic eye-movements KW - Auditory targets KW - Voluntary control KW - Task-performance KW - Latency KW - Prosaccade KW - Vergence KW - Stimuli KW - GAP Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141807 VL - 11 IS - 116 ER - TY - JOUR A1 - Glotzbach, Evelyn A1 - Mühlberger, Andreas A1 - Gschwendtner, Kathrin A1 - Fallgatter, Andreas J A1 - Pauli, Paul A1 - Herrmann, Martin J T1 - Prefrontal Brain Activation During Emotional Processing: A Functional Near Infrared Spectroscopy Study (fNIRS) JF - The Open Neuroimaging Journal N2 - The limbic system and especially the amygdala have been identified as key structures in emotion induction and regulation. Recently research has additionally focused on the influence of prefrontal areas on emotion processing in the limbic system and the amygdala. Results from fMRI studies indicate that the prefrontal cortex (PFC) is involved not only in emotion induction but also in emotion regulation. However, studies using fNIRS only report prefrontal brain activation during emotion induction. So far it lacks the attempt to compare emotion induction and emotion regulation with regard to prefrontal activation measured with fNIRS, to exclude the possibility that the reported prefrontal brain activation in fNIRS studies are mainly caused by automatic emotion regulation processes. Therefore this work tried to distinguish emotion induction from regulation via fNIRS of the prefrontal cortex. 20 healthy women viewed neutral pictures as a baseline condition, fearful pictures as induction condition and reappraised fearful pictures as regulation condition in randomized order. As predicted, the view-fearful condition led to higher arousal ratings than the view-neutral condition with the reappraise-fearful condition in between. For the fNIRS results the induction condition showed an activation of the bilateral PFC compared to the baseline condition (viewing neutral). The regulation condition showed an activation only of the left PFC compared to the baseline condition, although the direct comparison between induction and regulation condition revealed no significant difference in brain activation. Therefore our study underscores the results of previous fNIRS studies showing prefrontal brain activation during emotion induction and rejects the hypothesis that this prefrontal brain activation might only be a result of automatic emotion regulation processes. KW - fNIRS KW - Emotional processing KW - emotional regulation Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141714 VL - 5 ER - TY - JOUR A1 - Line, Samantha J. A1 - Barkus, Christopher A1 - Coyle, Clare A1 - Jennings, Katie A. A1 - Deacon, Robert M. A1 - Lesch, Klaus P. A1 - Sharp, Trevor A1 - Bannerman, David M. T1 - Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice JF - European Neuropsychopharmacology N2 - Human gene association studies have produced conflicting findings regarding the relationship between the 5-HT transporter (5-HTT) and anxiety. In the present study genetically modified mice were utilised to examine the effects of changes in 5-HTT expression on anxiety. In addition, the influence of 5-HTT expression on two innate “species-typical” behaviours (burrowing and marble burying) and body weight was explored. Across a range of models, 5-HTT overexpressing mice displayed reduced anxiety-like behaviour whilst 5-HTT knockout mice showed increased anxiety-like behaviour, compared to wildtype controls. In tests of species-typical behaviour 5-HTT overexpressing mice showed some facilitation whilst 5-HTT knockout mice were impaired. Reciprocal effects were also seen on body weight, as 5-HTT overexpressors were lighter and 5-HTT knockouts were heavier than wildtype controls. These findings show that variation in 5-HTT gene expression produces robust changes in anxiety and species-typical behaviour. Furthermore, the data add further support to findings that variation of 5-HTT expression in the human population is linked to changes in anxiety-related personality traits. KW - 5-HT KW - 5-HT transporter KW - Anxiety KW - Transgenic mice KW - Body weight Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141222 VL - 21 IS - 1 ER - TY - JOUR A1 - Egetemeir, Johanna A1 - Stenneken, Prisca A1 - Koehler, Saskia A1 - Fallgatter, Andreas J. A1 - Herrmann, Martin J. T1 - Exploring the neural basis of real-life joint action: measuring brain activation during joint table setting with functional near-infrared spectroscopy JF - FRONTIERS IN HUMAN NEUROSCIENCE N2 - Many every-day life situations require two or more individuals to execute actions together. Assessing brain activation during naturalistic tasks to uncover relevant processes underlying such real-life joint action situations has remained a methodological challenge. In the present study, we introduce a novel joint action paradigm that enables the assessment of brain activation during real-life joint action tasks using functional near-infrared spectroscopy (fNIRS). We monitored brain activation of participants who coordinated complex actions with a partner sitting opposite them. Participants performed table setting tasks, either alone (solo action) or in cooperation with a partner (joint action), or they observed the partner performing the task (action observation). Comparing joint action and solo action revealed stronger activation (higher [oxy-Hb]-concentration) during joint action in a number of areas. Among these were areas in the inferior parietal lobule (IPL) that additionally showed an overlap of activation during action observation and solo action. Areas with such a close link between action observation and action execution have been associated with action simulation processes. The magnitude of activation in these IPL areas also varied according to joint action type and its respective demand on action simulation. The results validate fNIRS as an imaging technique for exploring the functional correlates of interindividual action coordination in real-life settings and suggest that coordinating actions in real-life situations requires simulating the actions of the partner. KW - joint action KW - fNIRS KW - neuroimaging KW - social interaction KW - real-life interaction KW - simulation Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137054 N1 - Copyright © 2011 Egetemeir, Stenneken, Koehler, Fallgatter and Herrmann.This is an open-access article subject to a non-exclusive license between the authors and Frontiers Media SA,which permits use, distribution and reproduction in other forums, provided the original authors and source are credited andother Frontiers conditions are complied with. VL - 5 IS - 9, Artikel 95 ER - TY - JOUR A1 - Biehl, Stefanie C. A1 - Dresler, Thomas A1 - Reif, Andreas A1 - Scheuerpflug, Peter A1 - Deckert, Jürgen A1 - Herrmann, Martin J. T1 - Dopamine Transporter (DAT1) and Dopamine Receptor D4 (DRD4) Genotypes Differentially Impact on Electrophysiological Correlates of Error Processing JF - PLoS One N2 - Recent studies as well as theoretical models of error processing assign fundamental importance to the brain's dopaminergic system. Research about how the electrophysiological correlates of error processing—the error-related negativity (ERN) and the error positivity (Pe)—are influenced by variations of common dopaminergic genes, however, is still relatively scarce. In the present study, we therefore investigated whether polymorphisms in the DAT1 gene and in the DRD4 gene, respectively, lead to interindividual differences in these error processing correlates. One hundred sixty participants completed a version of the Eriksen Flanker Task while a 26-channel EEG was recorded. The task was slightly modified in order to increase error rates. During data analysis, participants were split into two groups depending on their DAT1 and their DRD4 genotypes, respectively. ERN and Pe amplitudes after correct responses and after errors as well as difference amplitudes between errors and correct responses were analyzed. We found a differential effect of DAT1 genotype on the Pe difference amplitude but not on the ERN difference amplitude, while the reverse was true for DRD4 genotype. These findings are in line with predictions from theoretical models of dopaminergic transmission in the brain. They furthermore tie results from clinical investigations of disorders impacting on the dopamine system to genetic variations known to be at-risk genotypes. KW - haplotypes KW - electroencephalography KW - basal ganglia KW - reaction time KW - dopaminergics KW - dopamine KW - ADHD KW - research errors Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137930 VL - 6 IS - 12 ER - TY - JOUR A1 - Gella, Alejandro A1 - Segura, Mònica A1 - Durany, Núria A1 - Pfuhlmann, Bruno A1 - Stöber, Gerald A1 - Gawlik, Micha T1 - Is Ankyrin a genetic risk factor for psychiatric phenotypes? JF - BMC Psychiatry N2 - Background Genome wide association studies reported two single nucleotide polymorphisms in ANK3 (rs9804190 and rs10994336) as independent genetic risk factors for bipolar disorder. Another SNP in ANK3 (rs10761482) was associated with schizophrenia in a large European sample. Within the debate on common susceptibility genes for schizophrenia and bipolar disorder, we tried to investigate common findings by analyzing association of ANK3 with schizophrenia, bipolar disorder and unipolar depression. Methods We genotyped three single nucleotide polymorphisms (SNPs) in ANK3 (rs9804190, rs10994336, and rs10761482) in a case-control sample of German descent including 920 patients with schizophrenia, 400 with bipolar affective disorder, 220 patients with unipolar depression according to ICD 10 and 480 healthy controls. Sample was further differentiated according to Leonhard's classification featuring disease entities with specific combination of bipolar and psychotic syndromes. Results We found no association of rs9804190 and rs10994336 with bipolar disorder, unipolar depression or schizophrenia. In contrast to previous findings rs10761482 was associated with bipolar disorder (p = 0.015) but not with schizophrenia or unipolar depression. We observed no association with disease entities according to Leonhard's classification. Conclusion Our results support a specific genetic contribution of ANK3 to bipolar disorder though we failed to replicate findings for schizophrenia. We cannot confirm ANK3 as a common risk factor for different diseases. KW - Ankyrin KW - genetic risk factor Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137769 VL - 11 IS - 103 ER - TY - JOUR A1 - Bartl, Jasmin A1 - Scholz, Claus-Jürgen A1 - Hinterberger, Margareta A1 - Jungwirth, Susanne A1 - Wichart, Ildiko A1 - Rainer, Michael K. A1 - Kneitz, Susanne A1 - Danielczyk, Walter A1 - Tragl, Karl H. A1 - Fischer, Peter A1 - Riederer, Peter A1 - Grünblatt, Edna T1 - Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzymegene JF - BMC Medical Genetics N2 - Background Insulin-degrading enzyme (IDE) is the ubiquitously expressed enzyme responsible for insulin and amyloid beta (Aβ) degradation. IDE gene is located on chromosome region 10q23-q25 and exhibits a well-replicated peak of linkage with Type 2 diabetes mellitus (T2DM). Several genetic association studies examined IDE gene as a susceptibility gene for Alzheimer's disease (AD), however with controversial results. Methods We examined associations of three IDE polymorphisms (IDE2, rs4646953; IDE7, rs2251101 and IDE9, rs1887922) with AD, Aβ42 plasma level and T2DM risk in the longitudinal Vienna Transdanube Aging (VITA) study cohort. Results The upstream polymorphism IDE2 was found to influence AD risk and to trigger the Aβ42 plasma level, whereas the downstream polymorphism IDE7 modified the T2DM risk; no associations were found for the intronic variant IDE9. Conclusions Based on our SNP and haplotype results, we delineate the model that IDE promoter and 3' untranslated region/downstream variation may have different effects on IDE expression, presumably a relevant endophenotype with disorder-specific effects on AD and T2DM susceptibility. KW - Insulin Degrading Enzyme Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137744 VL - 12 IS - 151 ER - TY - JOUR A1 - Herrmann, Martin J. A1 - Glotzbach, Evelyn A1 - Mühlberger, Andreas A1 - Gschwendtner, Kathrin A1 - Fallgatter, Andreas J. A1 - Pauli, Paul T1 - Prefrontal Brain Activation During Emotional Processing: A Functional Near Infrared Spectroscopy Study (fNIRS) JF - The Open Neuroimaging Journal N2 - The limbic system and especially the amygdala have been identified as key structures in emotion induction and regulation. Recently research has additionally focused on the influence of prefrontal areas on emotion processing in the limbic system and the amygdala. Results from fMRI studies indicate that the prefrontal cortex (PFC) is involved not only in emotion induction but also in emotion regulation. However, studies using fNIRS only report prefrontal brain activation during emotion induction. So far it lacks the attempt to compare emotion induction and emotion regulation with regard to prefrontal activation measured with fNIRS, to exclude the possibility that the reported prefrontal brain activation in fNIRS studies are mainly caused by automatic emotion regulation processes. Therefore this work tried to distinguish emotion induction from regulation via fNIRS of the prefrontal cortex. 20 healthy women viewed neutral pictures as a baseline condition, fearful pictures as induction condition and reappraised fearful pictures as regulation condition in randomized order. As predicted, the view-fearful condition led to higher arousal ratings than the view-neutral condition with the reappraise-fearful condition in between. For the fNIRS results the induction condition showed an activation of the bilateral PFC compared to the baseline condition (viewing neutral). The regulation condition showed an activation only of the left PFC compared to the baseline condition, although the direct comparison between induction and regulation condition revealed no significant difference in brain activation. Therefore our study underscores the results of previous fNIRS studies showing prefrontal brain activation during emotion induction and rejects the hypothesis that this prefrontal brain activation might only be a result of automatic emotion regulation processes. KW - fNIRS KW - Emotional processing KW - emotional regulation Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-97437 ER - TY - THES A1 - Lorenc, Simone Iris [geb. Lindhof] T1 - Das Münchhausen-by-proxy-Syndrom in Deutschland - erste Daten - T1 - The munchhausen by proxy syndrom in germany - first data - N2 - Erhebung erster Daten über das Vorliegen des Münchhausen-by-proxy-Syndroms, einer besonderen Form der Kindesmisshandlung, in Deutschland. Alle Kinderkliniken in Deutschland wurden im ersten Schritt nach Fällen und dem überblickten Zeitraum gefragt. Im zweiten Schritt folgte ein 23-seitiger Fragebogen mit Angaben u.a. zum Opfer, zu vorliegenden oder geschilderten Symptomen, zur Art des Missbrauchsnachweises, zur verursachenden Person, zum Verhalten der verursachenden Person, zum Partner der verursachenden Person, zu Geschwisterkindern, zu rechtlichen Folgen für die Opfer und die verursachende Person. Dem geschichtlichen Abspann folgte nach Auswertung unserer Daten eine Diskussion im Hinblick auf die derzeitige internationale Datenlage sowie ein Blick in die Zukunft. N2 - A first data survey in Germany on the existence of Munchausen by Proxy Syndrome, a particular form of child abuse. In the first step, all children's hospitals in Germany were asked about known cases and the period of time over which they occurred. In the second step, a 23-page questionnaire was distributed, requesting information about the victim, known or reported symptoms, the method used to detect the abuse, the offending person, the behavior of the offending person, the partner of the offending person, siblings of the victim, legal consequences for the victim and for the offending person, and other related information. The study concludes with a summary of important historical dates and events related to this topic, and a discussion regarding similar studies internationally and projections for the future. KW - Münchhausen-Syndrom der Angehörigen KW - Kindesmisshandlung KW - Mütter KW - verursachende Person KW - Münchhausen by proxy KW - Jugendamt KW - victims KW - munchhausen by proxy KW - symptoms KW - facticious disorder KW - mother Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-76941 ER - TY - THES A1 - Bange, Michael T1 - Einfluss von Quetiapin und Flupentixol auf ereigniskorrellierte Potenziale der Konfliktverarbeitung und neuropsychologische Testleistungen T1 - Effect of quetiapine and flupentixol on event-related potentials of conflict processing and neuropsychological test performance N2 - Hintergrund: Schizophrene Patienten zeigen eine verminderte Aktivität frontaler Hirnregionen (Hypofrontalität), was sich insbesondere auch in einer verminderten Aktivität des anterioren cingulären Cortex (ACC) äußert. Die Aktivität dieser Hirnregionen lässt sich medikamentös beeinflussen, wobei sich die Substanzen, die den typischen Antipsychotika zugeordnet werden, von denen der atypischen Antipsychotika grundlegend unterscheiden. Den atypischen Antipsychotika wird hierbei eine positive Wirkung zugesprochen, während typische Antipsychotika häufig keine, teilweise sogar auch negative Effekte auf die frontale Hirnaktivität zeigen. Ziel: Es existieren viele Arbeiten, in denen untersucht wird, inwieweit sich typische und atypische Antipsychotika in ihrer Wirkung auf die Frontalhirnfunktion unterscheiden. Es wurden jedoch bislang nur wenige Studien durchgeführt, in denen man nur eine Substanz der jeweiligen Medikamentengruppe miteinander verglichen hat. Daher war es Ziel der Studie, den generell positiven Effekt atypischer Antipsychotika auf frontale Hirnfunktionen, der sich in einer Vielzahl von Arbeiten gezeigt hat, in einer Vergleichsstudie zwischen Flupentixol und Quetiapin, welche im klinischen Alltag häufig Verwendung finden, nachzuweisen. Dies hätte Vorteile für die Patienten, da sich hierdurch eine bessere Indikationsstellung für das jeweilige Medikament durchführen ließe und damit eine bessere, differenzierte medikamentöse Therapie möglich wäre. Methoden: Es flossen die Daten von 21 Patienten in die Erhebung ein, wobei jeder Patient zu 2 Messzeitpunkten (t1 und t4) neurophysiologisch und neuropsychologisch untersucht wurde. Die psychometrischen Testungen fanden zu 4 Messzeitpunkten (t1, t2, t3 und t4) statt. Die Baselinemessung zu t1 erfolgte innerhalb der ersten 3 Tage im Rahmen eines stationären Aufenthaltes, die Messungen zu t2, t3 und t4 jeweils eine Woche später. 13 Patienten erhielten als Medikation Quetiapin, 8 Patienten Flupentixol. Zur Untersuchung der Frontalhirnaktivität wurde bei den Patienten eine EEGMessung durchgeführt, während sie eine konflikthafte Flankeraufgabe absolvieren mussten (Variable Attention Control, VAC-Aufgabe), bei der hoch-, mittel- und niedrig-interferente Stimuli präsentiert wurden. Ergebnisse: Die Ergebnisse der vorliegenden Studie gestalteten sich heterogen: Während auf kognitiver Ebene teilweise eine positive Wirkung bei den Patienten der Quetiapingruppe nachgewiesen werden konnte, ließ sich dies nicht mit entsprechenden Resultaten auf elektrophysiologischer Ebene korrelieren. In Bezug auf die subjektiv empfundene Lebensqualität zeigte sich bei den Patienten der Quetiapingruppe ein signifikanter Anstieg. Der in vielen Studien nachgewiesene positive Effekt atypischer Antipsychotika auf die Frontalhirnfunktion ließ sich in der vorliegenden Studie also nur eingeschränkt nachweisen. Schlussfolgerung: In der vorliegenden Studie wurden die Patienten in einem 4 Wochen andauernden Intervall untersucht. Einige zuvor durchgeführte Arbeiten, die Typika und Atypika in neurophysiologischen Versuchsanordnungen miteinander verglichen, wiesen ein größeres zeitliches Intervall (6 Wochen) zwischen Baseline und Follow-up auf als es in der vorliegenden Studie der Fall war (4 Wochen). Hierdurch könnte sich die Tatsache begründen lassen, dass sich in den neurophysiologischen Versuchen keine signifikant bessere Wirkung für Quetiapin nachweisen ließ. Darüber hinaus besteht die Möglichkeit, dass die Tatsache, dass ein Teil der Patienten zu t1 schon Medikation erhalten hatten, den Baselinewert eventuell erhöht haben könnte. Die Verbesserung der kognitiven Leistung lässt sich zum einen durch das Wirkprofil von Quetiapin, das zu den Atypika zählt begründen, zum anderen durch die signifikante Erhöhung der EPS in der Flupentixolgruppe, die deren Leistungen verschlechtert haben könnten. Die subjektiv empfundene Lebensqualität konnte Quetiapin im Vergleich zu Flupentixol deutlich verbessern. Hierbei ist zu erwähnen, dass die Flupentixolgruppe schon zu t1 eine Punktzahl vorweisen konnte, die nur wenig Raum für Verbesserung ließ und die Tatsache, dass der Grad der EPS deutlich höher war als bei der Quetiapingruppe, was eine weitere Verbesserung der subjektiv empfundenen Lebensqualität wahrscheinlich nicht zuließ. N2 - Background: Schizophrenic patients show reduced activity in frontal brain regions (Hypofrontality), which in particular is expressed also in a reduced activity of the anterior cingulate cortex (ACC) . The activity of these brain regions can be affected by drugs, wherein the substances associated to typical antipsychotics are fundamentally different from atypical Antipsychotics . The atypical antipsychotics are attributed to a positive effect, while typical antipsychotics don't, some even have negative effects on the frontal brain activity. Target: There are many Trials showing how typical and atypical antipsychotics differ concerning their effect on frontal brain activity. There are only a few studies in which only one substance of each class are compared to each other. Therefore it was the aim of the study to show the overall positive effect of atypical antipsychotics on frontal brain functions. The two substances compared to each other were quetiapin and flupentixol. Methods: In the survey the data from 21 patients were included. In each patient at 2 appointments(t1 and t4), neurophysiological and neuropsychological was investigated. The psychometric test results were evaluated at 4 dates (T1, t2, t3 and t4) instead. The baseline measurement at t1 occurred within the first 3 days as part of an inpatient stay .The measurements at t2, t3 and t4 were made one week later. 13 patients were medicated with quetiapine, 8 patients with flupentixol. To examine the frontal brain activity in these patients an EEG was performed while they had to complete a conflictual variable Attention Control-task). Results: The results of the present study are heterogeneous: While the cognitive level partly showed a positive effect in patients medicated with Quetiapincorresponding results,correlating results on electrophysiological level did not occur. In Terms of the perceived quality of life a significant increase was observed in the patients medicated with Quetiapin. The positive effect shown in many trials did only occur partly in the recent study. Conclusion: In the present study, patients were examined within an interval of 4 weeks. In some trials carried out earlier, the medication was applied over a larger interval of time (6 weeks) between baseline and Follow-up, as it was only 4 weeks in the case of the present study. This could be one reason for the lacking effect by the quetiapin. The fact that there were patients receiving medication at t1 already could also increase the data collected at baseline. The subjectively perceived quality of life among the patients medicated with Quetiapine significantly improved compared with flupentixol. It is worth mentioning that the score among the Flupentixol medicated patients at t1 was already quite high, so there was only little room for improvement, and the fact that there were great EPS symptoms among the Fulpentixol-Patients maybe did not allow a score even higher. KW - Ereigniskorreliertes Potenzial KW - Event related potentials Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-73714 ER - TY - THES A1 - Marschelke, Julia Caterine T1 - Handlungsüberwachung bei Schizophrenien und Zykloiden Psychosen - Ein Vergleich der diagnostischen Untergruppen anhand der "error-related negativity" (ERN) T1 - Performance monitoring in schizophrenia and cycloid psychoses-a comparison of the diagnostic subgroups on the basis of the "error-related negativity" (ERN) N2 - In der vorliegenden Arbeit sollte anhand der error-related negativity (ERN) eine eingeschränkte Fehlerwahrnehmung und im weiteren Sinne eine eingeschränkte Handlungskontrolle bei Patienten mit Erkrankungn aus dem schizophrenen Formenkreis im Vergleich zu gesunden Probanden dargestellt werden. Für diesen Vergleich wurde zusätzlich die error- positivity (Pe) herangezogen. Anhand dieser Parameter erfolgte zusätzlich ein Vergleich der Patienten mit einer klassischen Schizophrenie und solchen mit einer Zykloiden Psychose mit Blick auf die bereits existierende klinische Differenzierung gemäß Leonhard. Als Ergebnis ließen sich im Vergleich zu den Kontrollprobanden eine eingeschränkte ERN und eine eingeschränkte Pe bei beiden Patientengruppen feststellen. Die Hypothese, dass Patienten mit einer Zykloiden Psychose sich nicht nur klinisch, sondern auch elektrophysiologisch von den Patienten mit einer klassischen Schizophrenie unterscheiden, ließ sich anhand der ERN und der Pe nicht untermauern. Anders als angenommen wiesen die Patienten mit einer Zykloiden Psychose keine weniger starke Einschränkung der beiden elektrophysiologischen Parameter auf. N2 - In this study we used the error-related negativity (ERN) to show a restricted error- perception and in a broader sense, a limited executive control in patients with schizophrenia spectrum psychoses compared to healthy subjects. Additionally we took the error-positivity (Pe) into account in order to compare these groups. Moreover we tried to differentiate patients with a classical schizophrenia from patients with a cycloid psychosis based on the parameters mentioned above in view of the already existing clinical differentiation according to Leonhard. As a result both patient groups showed lower amplitudes for the ERN and the Pe. The hypothesis that patients with cycloid psychosis differ not only clinically but also electrophysiologically from the patients with classical schizophrenia could not be corroborated by means of the ERN and the Pe. Unlike our assumption patients with a cycloid psychosis did not show less severe restrictions in both electrophysiological parameters compared to those with a classical schizophrenia. KW - Schizophrenie KW - Zykloide Psychose KW - error-related negativity KW - Schizophrenia KW - cycloid psychoses KW - error-related negativity Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-71169 ER - TY - JOUR A1 - Gella, Alejandro A1 - Segura, Monica A1 - Durany, Nuria A1 - Pfuhlmann, Bruno A1 - Stoeber, Gerald A1 - Gawlik, Micha T1 - Is Ankyrin a specific genetic risk factor for psychiatric phenotypes? N2 - Background: Genome wide association studies reported two single nucleotide polymorphisms in ANK3 (rs9804190 and rs10994336) as independent genetic risk factors for bipolar disorder. Another SNP in ANK3 (rs10761482) was associated with schizophrenia in a large European sample. Within the debate on common susceptibility genes for schizophrenia and bipolar disorder, we tried to investigate common findings by analyzing association of ANK3 with schizophrenia, bipolar disorder and unipolar depression. Methods: We genotyped three single nucleotide polymorphisms (SNPs) in ANK3 (rs9804190, rs10994336, and rs10761482) in a case-control sample of German descent including 920 patients with schizophrenia, 400 with bipolar affective disorder, 220 patients with unipolar depression according to ICD 10 and 480 healthy controls. Sample was further differentiated according to Leonhard’s classification featuring disease entities with specific combination of bipolar and psychotic syndromes. Results: We found no association of rs9804190 and rs10994336 with bipolar disorder, unipolar depression or schizophrenia. In contrast to previous findings rs10761482 was associated with bipolar disorder (p = 0.015) but not with schizophrenia or unipolar depression. We observed no association with disease entities according to Leonhard’s classification. Conclusion: Our results support a specific genetic contribution of ANK3 to bipolar disorder though we failed to replicate findings for schizophrenia. We cannot confirm ANK3 as a common risk factor for different diseases. KW - Schizophrenie Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68732 ER - TY - THES A1 - Wittlich, Meike T1 - Interaktionen von allelischen Variationen von 5-HTTLPR mit Umweltfaktoren bei Patienten mit adulter Aufmerksamkeits-Defizit-/ Hyperaktivitäts-Störung T1 - Interactions of allelic variation of 5-HTTLPR with life events in a sample of patients with adult ADHD N2 - Dysfunktionen des serotonergen Neurotransmittersystems, innerhalb dessen die allelischen Variationen des 5-HTTLPR-Polymorphismus wiederum einen zentrale Rolle einnehmen, werden für die Genese verschiedener psychischer Erkrankungen diskutiert. Untersucht wurde die Interaktion zwischen der allelischen Variationen des 5-HTTLPR-Polymorphismus und Lebensereignissen, die mit Hilfe des Life History Calendar von Caspi bei 123 aADHS-Patienten erfasst wurden. Die Teilnehmer wurden über Lebenserfahrungen bis zu ihrem 21. Lebensjahr genau befragt, die so in additiver Wertung in den Life-Event-Effekt einflossen. Zudem wurden mit Hilfe der Persönlichkeitstests TPQ und NEO-PI-R Punktescores erhoben. Eine Marker*Life Event-Interaktion wurde nachgewiesen. Bei aAHDS-Patienten, die die homozygot lange Variante des 5-HTTLPR-Polymorphismus tragen, ist eine höhere Zahl an erlebten Life Events mit einem größerem Risiko assoziiert, eine Cluster-B-Persönlichkeitsstörung zu entwickeln. Eine geringere Anzahl an Life Events ist assoziiert mit einem geringerem Risiko für Persönlichkeitsstörungen. N2 - Dysfunctions of the serotonergic neurotransmitter system are discussed in the etiology of various mental diseases. We investigated the interaction between the allelic variation of the 5-HTTLPR polymorphism and life events that were assessed with the aid of a life history calendar at 123 adult ADHD-patients. The participants were questioned about life events up to the age of 21. Moreover personality dimensions were assessed by Tridimensional Personality Questionnaire (TPQ) and NEO-Personality Inventory. A marker * Life Event interaction was detected. In aADHD-patients who carry the homozygous long variant of the 5-HTTLPR polymorphism, a higher number of experienced life events is associated with an increased risk of cluster B personality disorder, smaller number of life events is associated with a lower risk of cluster B personality disorders. KW - Aufmerksamkeits-Defizit-Syndrom KW - Serotonin KW - adulte ADHS KW - 5-HTT KW - 5-HTTLPR KW - Gen-Umwelt-Interaktion KW - ADHD KW - serotonin KW - 5-HTT KW - life events Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-70087 ER -